ADMA Biologics Inc

ADMA’s operations are primarily U.S.-based, with manufacturing conducted at its FDA-licensed plasma fractionation and purification facility in Boca Raton, Florida. The company’s plasma sourcing footprint includes ten FDA-licensed source plasma collection centers across the United States, which supply raw plasma for internal production and also support third-party plasma sales. While the core commercial focus is the U.S. market, ADMA has an ex-U.S. economic interest through a license with Biotest AG for ASCENIV commercialization in Europe and certain countries in Northern Africa and the Middle East, structured as royalties over a 20-year period from first commercial sale in the territory. Geographic exposure matters mainly through U.S. regulatory oversight (FDA inspections), domestic plasma availability, and the logistics of cold-chain storage and inventory given a long production cycle time.

ADMA’s business is exposed to plasma supply and manufacturing execution risk: if it cannot obtain adequate FDA-approved source and high-titer plasma, or if plasma is damaged/contaminated, production and product availability can be disrupted. Regulatory risk is significant because both segments and key facilities are subject to periodic FDA inspections, and adverse findings could restrict operations or delay releases. Commercially, revenue concentration with a small number of distributors increases exposure to purchasing behavior, contract terms, and channel inventory dynamics. The company also faces cybersecurity and privacy compliance risk due to donor data collected at plasma centers, and it has additional risk from reliance on third parties for certain filling/packaging/testing activities. More broadly, the plasma products market is highly competitive, and new infectious disease outbreaks or precautionary public health measures could impair plasma procurement and manufacturing continuity.